JP2000515132A - 安定な非中毒性処方物中の非経口パクリタキセル - Google Patents

安定な非中毒性処方物中の非経口パクリタキセル

Info

Publication number
JP2000515132A
JP2000515132A JP10504432A JP50443298A JP2000515132A JP 2000515132 A JP2000515132 A JP 2000515132A JP 10504432 A JP10504432 A JP 10504432A JP 50443298 A JP50443298 A JP 50443298A JP 2000515132 A JP2000515132 A JP 2000515132A
Authority
JP
Japan
Prior art keywords
paclitaxel
dma
peg
pharmaceutical composition
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10504432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515132A5 (cg-RX-API-DMAC7.html
Inventor
エス． アンダーソン，ボージェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24699210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2000515132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2000515132A publication Critical patent/JP2000515132A/ja
Publication of JP2000515132A5 publication Critical patent/JP2000515132A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP10504432A 1996-06-28 1997-06-26 安定な非中毒性処方物中の非経口パクリタキセル Ceased JP2000515132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/672,594 1996-06-28
US08/672,594 US5877205A (en) 1996-06-28 1996-06-28 Parenteral paclitaxel in a stable non-toxic formulation
PCT/US1997/011503 WO1998000128A1 (en) 1996-06-28 1997-06-26 Parenteral paclitaxel in a stable non-toxic formulation

Publications (2)

Publication Number Publication Date
JP2000515132A true JP2000515132A (ja) 2000-11-14
JP2000515132A5 JP2000515132A5 (cg-RX-API-DMAC7.html) 2005-03-10

Family

ID=24699210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10504432A Ceased JP2000515132A (ja) 1996-06-28 1997-06-26 安定な非中毒性処方物中の非経口パクリタキセル

Country Status (9)

Country Link
US (2) US5877205A (cg-RX-API-DMAC7.html)
EP (1) EP0920311A4 (cg-RX-API-DMAC7.html)
JP (1) JP2000515132A (cg-RX-API-DMAC7.html)
CN (1) CN1165300C (cg-RX-API-DMAC7.html)
AU (1) AU722617B2 (cg-RX-API-DMAC7.html)
CA (1) CA2259297C (cg-RX-API-DMAC7.html)
NO (1) NO986165L (cg-RX-API-DMAC7.html)
NZ (1) NZ333737A (cg-RX-API-DMAC7.html)
WO (1) WO1998000128A1 (cg-RX-API-DMAC7.html)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111211A1 (ja) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US9434822B2 (en) 2004-09-22 2016-09-06 Nippon Kayaku Kabushiki Kaisha Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
PL201329B1 (pl) * 1998-02-05 2009-03-31 Novartis Ag Preparat farmaceutyczny w postaci koncentratu infuzyjnego
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
KR100446959B1 (ko) * 1998-04-02 2004-11-03 김종국 파클리탁셀주사제조성물
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
WO2000037050A1 (en) * 1998-12-22 2000-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
PL350075A1 (en) * 2000-02-02 2002-11-04 Univ Florida State Res Found Taxane formulations having improved solubility
AU2001258872C1 (en) 2000-05-12 2005-05-26 Samyang Biopharmaceuticals Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
WO2002009695A1 (en) * 2000-08-02 2002-02-07 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
JP2005504070A (ja) * 2001-09-13 2005-02-10 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 化学塞栓用油性パクリタキセル組成物及び処方物並びにその製造方法
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
BR0214277A (pt) * 2001-11-30 2004-09-21 Bristol Myers Squibb Co Solvatos de paclitaxel
WO2003057128A2 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
US20040213837A1 (en) * 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
US20050129719A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Concentrated emulsion formulation for silatecan
US20050220835A1 (en) * 2004-03-30 2005-10-06 Jayaraman Ramesh B Agent eluting bioimplantable devices and polymer systems for their preparation
CA2615939A1 (en) * 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
ES2584840T3 (es) * 2006-10-03 2016-09-29 Nippon Kayaku Kabushiki Kaisha Compuesto de un derivado de resorcinol con un polímero
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
CN102038636B (zh) * 2009-10-23 2014-08-13 天士力控股集团有限公司 一种含有螯合剂的紫杉烷类药物溶液及其制备方法
CN102038634B (zh) * 2009-10-23 2014-12-10 天士力控股集团有限公司 一种含有助溶剂的紫杉烷类药物溶液及其制备方法
CN102038635A (zh) * 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
TWI472340B (zh) * 2010-11-10 2015-02-11 Tasly Holding Group Co Ltd Taxanes containing solution and a preparation method of the co-solvent
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN109464382B (zh) * 2019-01-08 2020-10-09 四川大学 一种可注射的高载药量的紫杉醇凝胶及其制备方法和应用
JP2024537910A (ja) * 2021-10-21 2024-10-16 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー 安定した希釈準備済みカルフィルゾミブ組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5430057A (en) * 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434822B2 (en) 2004-09-22 2016-09-06 Nippon Kayaku Kabushiki Kaisha Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
WO2007111211A1 (ja) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US8808749B2 (en) 2009-05-15 2014-08-19 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of bioactive substance having hydroxy group
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
US9346923B2 (en) 2011-09-11 2016-05-24 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer

Also Published As

Publication number Publication date
AU722617B2 (en) 2000-08-10
NO986165D0 (no) 1998-12-28
EP0920311A4 (en) 2001-10-04
NO986165L (no) 1999-02-25
CA2259297C (en) 2003-12-16
CA2259297A1 (en) 1998-01-08
NZ333737A (en) 2000-02-28
US6107333A (en) 2000-08-22
EP0920311A1 (en) 1999-06-09
AU3647897A (en) 1998-01-21
WO1998000128A1 (en) 1998-01-08
CN1228022A (zh) 1999-09-08
US5877205A (en) 1999-03-02
CN1165300C (zh) 2004-09-08

Similar Documents

Publication Publication Date Title
JP2000515132A (ja) 安定な非中毒性処方物中の非経口パクリタキセル
US5430057A (en) Parenteral busulfan for treatment of malignant disease
AU734695B2 (en) Pharmaceutical compositions containing plasma protein
EP2480207B1 (en) Micelle encapsulation of therapeutic agents
FI92556C (fi) Menetelmä intravenoosisen farmaseuttisen koostumuksen valmistamiseksi
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
AU775158B2 (en) Water-miscible pharmaceutical compositions of paclitaxel
Sugahara et al. Complete regression of xenografted human carcinomas by a paclitaxel–carboxymethyl dextran conjugate (AZ10992)
Pes et al. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound
US20030082229A1 (en) Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
Ahmed et al. INVESTIGATION OF ENHANCEMENT DELIVERY OF CAMPTOTHECIN THROUGH HYDROXY PROPYL-B-CYCLODEXTRIN COMPLEXATION, LOADED ON PEGYLATED RUTIN LIPOSOMES.
HK1021704A (en) Parenteral paclitaxel in a stable non-toxic formulation
KR20050060981A (ko) 수용성 파클리탁셀 프로드럭 화합물 및 플라보노이드계화합물을 포함하는 경구용 항암 조성물
CZ18181U1 (cs) Farmaceutický prostředek s obsahem taxanového derivátu, určený pro přípravu infúzního roztoku

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080212

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080826